News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

01/07/2020 | CureVac AG

CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study

Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming scientific conference    
12/20/2019 | Curetis GmbH

Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. Commercial launch in the U.S. expected for Q1-2020
12/19/2019 | CureVac AG

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term Genmab will provide CureVac with a USD 10 million upfront payment and make an equity investment in CureVac of 20 million euro CureVac eligible to rece...
An Aster flower in nature.
12/03/2019 | Eberhard Karls Universität Tübingen

Fungus produces active agent in a medicinal herb

Tübingen and Dresden researchers discover that a fungus in Tatarinow’s aster produces bioactive agents
12/02/2019 | CureVac AG

CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs
11/28/2019 | Ovesco Endoscopy AG

EFTR is a useful tool for staging of early colorectal cancer and simultaneously can be sufficient treatment for low-risk lesions

In 156 patients with histologic evidence of adenocarcinoma, EFTR was technically successful in 92.3 % and R0 resection was achieved in 71.8 %. Exact risk stratification was possible in 99.3 %. Severe procedure-related adverse events were recorded in 3.9 % of patients.
11/25/2019 | Curetis GmbH

Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize

Vienna, Austria,and Holzgerlingen, Germany, November 25, 2019, 10:00 am CET-Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Geneticswas awarded the 2019 MERCUR Innovation Prize by the Vienna Economic Chamber in...
11/08/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

Tübingen (Germany), November 08, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced the successful conclusion and top-line results of its Phase I clinical trial for its lead drug candidate ATR-002. The official report will be released in January 2020.
10/31/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics to present at the BIO-Europe in Hamburg

Tübingen (Germany), October 31, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.
Handshake between Michael J. Collins (CEM) and Dr. Steffen Huettner (Intavis).
10/29/2019 | Intavis AG

CEM Corporation acquires key assets of Intavis Bioanalytical Instruments

Matthews, N.C. October 25th, 2019 – CEM Corporation today announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters in Cologne Germany. The acquisition allows CEM to strengthen its product offering in the Life Sciences for proteomics, in-situ hybridizat...
10/28/2019 | Curetis GmbH

Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic sus...
FOCUS label Growth Champion 2020
10/17/2019 | Bentley InnoMed GmbH

Hechingen-based medical technology company Bentley is FOCUS Growth Champion 2020

The success story continues. Following on from Bentley celebrating its tenth anniversary this summer, the company is now marking the next highlight in its short history – the Hechingen-based medical technology company has been named FOCUS Growth Champion 2020. Together with Statista, one of the world’s biggest online statistics platforms, the magaz...
10/15/2019 | DEKRA SE

DEKRA Becomes First Notified Body in Europe for In-Vitro Diagnostics under New IVD Regulation

DEKRA has become the first certification company to be recognized as a Notified Body by the European Commission under the new EU regulation on in-vitro diagnostics. Under this new regulation, considerably stricter requirements will apply to manufacturers of in-vitro diagnostics (IVDs) in the European Union starting from May 26, 2022. IVDs are medic...
09/27/2019 | Insilico Biotechnology AG

Insilico and Janssen take another step towards predictive biomanufacturing: Digital Twins allow for accelerated timelines in cell line development for biologics production

Insilico Biotechnology AG and the Janssen Pharmaceutical Companies of Johnson & Johnson announced an agreement to apply Insilico's predictive Digital Twins for the early selection of high-performing cells to further boost efficiency and throughpu...
09/16/2019 | Curetis GmbH

CuretisGroup Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation

R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdb, Partner to fund R&D and obtains option to license ARESdb and ARES Technology Platform for human clinical diagnostic use
09/13/2019

Partners from across Europe to host event in Galway to support companion diagnostics SMEs

WestBIC, CÚRAM, the Science Foundation Ireland Research Centre for Medical Devices at NUI Galway, and their European partners in Codex4SMEs Information and Networking Event are to host the Interreg North-West Europe project Codex4SMEs (Companion Diagnostics Expedited for Small and Medium-sized Enterprises) on Wednesday, 18 September, at Hotel Meyri...
09/04/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics takes part in four conferences in the upcoming months

Dr. Rainer Lichtenberger, CEO of Atriva, will represent the Company and will be available for networking and one-on-one meetings at the following events:
08/28/2019 | immatics biotechnologies GmbH

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.
A person wearing a purple-colored pair of gloves inserts the thin cannula of a syringe into the organ-on-a-chip system.
08/27/2019 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

Retina-on-a-chip provides powerful tool for studying eye disease

Impact statement: New technology that recreates some of the complexity of the human retina may help scientists study eye disease and screen for drug side effects that harm the eye.
08/13/2019 | CureVac AG

CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative Research Agreement (“CRA”) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.